Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 66.70% is 114% above its 3-year average of 31.17%, near the high end of its 3-year range (-68.64%–73.45%).
213.13% above its 12-month average of 21.30%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2025 (2025-12-31): 59.09%.
EBITDA MARGIN
66.70%
EBITDA MARGIN AVG TTM
21.30%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+213.13%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$215.07M
EBITDA Margin
66.70%
TTM Avg
21.30%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.51M
EBITDA Margin
12.17%
TTM Avg
10.71%
3Y Avg
-1.62%
5Y Avg
-12.53%
Market Cap
$214.35M
EBITDA Margin
-847.24%
TTM Avg
-1408.92%
3Y Avg
-1408.92%
5Y Avg
-1408.92%
Market Cap
$217.34M
EBITDA Margin
-646.93%
TTM Avg
-391.16%
3Y Avg
-256.59%
5Y Avg
-321.84%
Market Cap
$211.80M
EBITDA Margin
43.70%
TTM Avg
-4.00%
3Y Avg
-127.66%
5Y Avg
-437.76%
Market Cap
$218.26M
EBITDA Margin
-533986.11%
TTM Avg
-544963.54%
3Y Avg
-316138.98%
5Y Avg
-211520.31%
Market Cap
$209.49M
EBITDA Margin
-2994.14%
TTM Avg
-1551.99%
3Y Avg
-854.53%
5Y Avg
-625.57%
Market Cap
$221.87M
EBITDA Margin
29.55%
TTM Avg
-2937.39%
3Y Avg
-39292.92%
5Y Avg
-29539.33%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $215.07M | 66.70% | 21.30% | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.51M | 12.17% | 10.71% | -1.62% | -12.53% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.35M | -847.24% | -1408.92% | -1408.92% | -1408.92% |
| Alector, Inc. (ALEC)vs › | $217.34M | -646.93% | -391.16% | -256.59% | -321.84% |
| Compugen Ltd. (CGEN)vs › | $211.80M | 43.70% | -4.00% | -127.66% | -437.76% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $218.26M | -533986.11% | -544963.54% | -316138.98% | -211520.31% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $209.49M | -2994.14% | -1551.99% | -854.53% | -625.57% |
| Sionna Therapeutics, Inc. (SION)vs › | $209.27M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $221.87M | 29.55% | -2937.39% | -39292.92% | -29539.33% |
| Pro-Dex, Inc. (PDEX)vs › | $206.04M | 18.55% | 18.23% | 16.57% | 15.69% |
Gross Margin
87.2%
EBITDA Margin
66.7%
Operating Margin
66.7%
Net Margin
74.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 59.09% |
| 2025-06-30 | 73.45% |
| 2024-12-31 | -68.64% |
| 2024-06-30 | 61.51% |
| 2023-12-31 | 14.87% |
| 2023-06-30 | 46.74% |
